Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data.

IF 6.1 2区 医学 Q1 CHEMISTRY, MEDICINAL
Izabela Szymkowiak, Justyna Marcinkowska, Malgorzata Kucinska, Milosz Regulski, Marek Murias
{"title":"Resveratrol Bioavailability After Oral Administration: A Meta-Analysis of Clinical Trial Data.","authors":"Izabela Szymkowiak, Justyna Marcinkowska, Malgorzata Kucinska, Milosz Regulski, Marek Murias","doi":"10.1002/ptr.8379","DOIUrl":null,"url":null,"abstract":"<p><p>Annually, a growing body of studies substantiates the health advantages of polyphenolic compounds, yet their practical application is constrained by swift metabolism and low bioavailability. Resveratrol, a stilbene derivative showcasing typical polyphenolic traits, is particularly noteworthy. Despite abundant bioavailability data from in vitro and animal studies, applying these findings to humans demands nuanced consideration. The objective of this article is to conduct a meta-analysis on clinical trial data, systematically assessing the oral bioavailability of resveratrol and deriving meaningful insights into its efficacy in humans. To achieve this goal, we thoroughly examined publications across five major global databases: PubMed, Cochrane Library, Scopus, Embase, and Science Direct. The study exclusively included clinical trials involving healthy adults, where pharmacokinetic parameters were measured following the oral administration of at least one dose of resveratrol as a single preparation. For the meta-analysis data extraction, the mean score and standard deviation (SD) were included. Heterogeneity, degree of inconsistency between studies, and meta-regression were assessed. From these searches, we scrutinized data from 84 oral administrations encompassing nine resveratrol doses ranging from 25 to 5000 mg. Our findings indicate a linear increase in the amount of free resveratrol entering the bloodstream with the administered dose, while T<sub>max</sub> values remain unaffected. The mean maximum plasma concentration of resveratrol (31.07 ng/mL) closely mirrors the mean C<sub>max</sub> observed in the group administered a medium resveratrol dose ranging from 100 to 500 mg (33.59 ng/mL). This similarity implies the appropriateness of employing these specific doses of resveratrol, taking into consideration both its bioavailability and very low risk of potential side effects. However, the analysis of available human oral bioavailability data is constrained by methodological inconsistencies prevalent in existing studies. The meta-analysis underscores substantial heterogeneity, underscoring the imperative for multiple studies to rectify this prevailing trend.</p>","PeriodicalId":20110,"journal":{"name":"Phytotherapy Research","volume":" ","pages":""},"PeriodicalIF":6.1000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phytotherapy Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/ptr.8379","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

Annually, a growing body of studies substantiates the health advantages of polyphenolic compounds, yet their practical application is constrained by swift metabolism and low bioavailability. Resveratrol, a stilbene derivative showcasing typical polyphenolic traits, is particularly noteworthy. Despite abundant bioavailability data from in vitro and animal studies, applying these findings to humans demands nuanced consideration. The objective of this article is to conduct a meta-analysis on clinical trial data, systematically assessing the oral bioavailability of resveratrol and deriving meaningful insights into its efficacy in humans. To achieve this goal, we thoroughly examined publications across five major global databases: PubMed, Cochrane Library, Scopus, Embase, and Science Direct. The study exclusively included clinical trials involving healthy adults, where pharmacokinetic parameters were measured following the oral administration of at least one dose of resveratrol as a single preparation. For the meta-analysis data extraction, the mean score and standard deviation (SD) were included. Heterogeneity, degree of inconsistency between studies, and meta-regression were assessed. From these searches, we scrutinized data from 84 oral administrations encompassing nine resveratrol doses ranging from 25 to 5000 mg. Our findings indicate a linear increase in the amount of free resveratrol entering the bloodstream with the administered dose, while Tmax values remain unaffected. The mean maximum plasma concentration of resveratrol (31.07 ng/mL) closely mirrors the mean Cmax observed in the group administered a medium resveratrol dose ranging from 100 to 500 mg (33.59 ng/mL). This similarity implies the appropriateness of employing these specific doses of resveratrol, taking into consideration both its bioavailability and very low risk of potential side effects. However, the analysis of available human oral bioavailability data is constrained by methodological inconsistencies prevalent in existing studies. The meta-analysis underscores substantial heterogeneity, underscoring the imperative for multiple studies to rectify this prevailing trend.

口服白藜芦醇后的生物利用率:临床试验数据的元分析。
每年都有越来越多的研究证实了多酚化合物对健康的益处,但它们的实际应用却受到新陈代谢快和生物利用率低的限制。白藜芦醇是一种二苯乙烯衍生物,具有典型的多酚类特征,尤其值得注意。尽管体外和动物研究提供了丰富的生物利用率数据,但要将这些研究结果应用于人体,还需要进行细致的考虑。本文的目的是对临床试验数据进行荟萃分析,系统地评估白藜芦醇的口服生物利用度,并就其对人体的功效提出有意义的见解。为了实现这一目标,我们全面研究了全球五大数据库中的出版物:PubMed、Cochrane Library、Scopus、Embase 和 Science Direct。研究只包括涉及健康成人的临床试验,这些试验在口服至少一剂白藜芦醇单方制剂后测量了药代动力学参数。荟萃分析的数据提取包括平均分和标准差(SD)。对异质性、研究间的不一致程度和元回归进行了评估。通过这些搜索,我们仔细研究了 84 项口服白藜芦醇的数据,包括 9 种白藜芦醇剂量,从 25 毫克到 5000 毫克不等。我们的研究结果表明,随着给药剂量的增加,进入血液的游离白藜芦醇量呈线性增加,而Tmax值则不受影响。白藜芦醇的平均最大血浆浓度(31.07 纳克/毫升)与中等白藜芦醇剂量(100 至 500 毫克)组的平均 Cmax 值(33.59 纳克/毫升)非常接近。考虑到白藜芦醇的生物利用度和极低的潜在副作用风险,这种相似性意味着使用这些特定剂量的白藜芦醇是合适的。然而,对现有人体口服生物利用率数据的分析受到现有研究中普遍存在的方法不一致的限制。荟萃分析强调了大量的异质性,强调必须进行多项研究来纠正这一普遍趋势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Phytotherapy Research
Phytotherapy Research 医学-药学
CiteScore
12.80
自引率
5.60%
发文量
325
审稿时长
2.6 months
期刊介绍: Phytotherapy Research is an internationally recognized pharmacological journal that serves as a trailblazing resource for biochemists, pharmacologists, and toxicologists. We strive to disseminate groundbreaking research on medicinal plants, pushing the boundaries of knowledge and understanding in this field. Our primary focus areas encompass pharmacology, toxicology, and the clinical applications of herbs and natural products in medicine. We actively encourage submissions on the effects of commonly consumed food ingredients and standardized plant extracts. We welcome a range of contributions including original research papers, review articles, and letters. By providing a platform for the latest developments and discoveries in phytotherapy, we aim to support the advancement of scientific knowledge and contribute to the improvement of modern medicine.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信